



BIOCORP accelerates its Business Development

Supporting its e-health expertise in endocrinology and neurology

Issoire, April 7th, 2016 – BIOCORP, (FR0012788065 – ALCOR / PEA-PME eligible), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices, announced today the acceleration of its connected devices developments in collaboration with several international pharmaceutical laboratories enhancing therefore Its expertise in e-health via two connected devices: DataPen and Easylog.

« These latest developments confirm the relevance of our strategy based on breakthrough technologies as illustrated by the development of connected devices adapted to the follow-up of patients suffering from chronic diseases. We benefit from a competitive edge to address the global pharmaceutical industry marketplace. This development highlights our strong aptitude to anticipate the pharmaceutical market's needs in e-health and to honors our commitments made at the time of our listing on Alternext”, commented Jacques Gardette, Biocorp's CEO and founder.

In 2015, Biocorp announced several developments in e-health such as the commercialization of Datapen in February and Easylog in October. In June 2015, the company also signed two partnership agreements in drug administration: two new license agreements with the company NUOVA OMPI for NewSeal and Carpséal systems and one with the Japanese company NIPRO for the NewGuard system.

About BIOCORP

Founded in 2004 in Issoire (near Clermont-Ferrand, France), Biocorp is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as 'Innovative Company' by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, Biocorp is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, Biocorp continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 43 employees.

Biocorp is listed on Alternext since July 2015 (FR0012788065 – ALCOR). For more information, please visit: www.biocorp.fr

Follow us on Twitter [@BIOCORPSystems](https://twitter.com/BIOCORPSystems)

Contacts

Biocorp

Jacques Gardette
CEO

investisseurs@biocorp.fr

Eric Dessertenne
Head of Business Development

Press relations

ALIZE RP

Caroline Carmagnol & Wendy Rigal

01 44 64 36 66 - 06 48 82 18 94

biocorp@alizerp.com

